We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Trial Assessing Antiviral Drug DAS181 Against COVID-19 Begins Enrolling Patients

News   Jul 15, 2020 | Original story from Keck Medicine of USC

 
Trial Assessing Antiviral Drug DAS181 Against COVID-19 Begins Enrolling Patients

Keck Medicine of USC physicians are participating in a clinical trial to evaluate the safety and efficacy of an antiviral drug, DAS181, as a possible treatment for hospitalized patients with severe COVID-19. Credit: Ricardo Carrasco III

 
 
Advertisement
 

RELATED ARTICLES

UK Government-Funded COVID-19 Vaccine Phase 1/2 Trials Report Positive Data

News

A new COVID-19 vaccine candidate – VLA2001 – developed by Valneva has shown positive results in a UK Government-funded Phase I/II clinical trial, according to a press release.

READ MORE

Molecular Devices Opens Organoid Innovation Center

News

Molecular Devices, LLC., has opened an Organoid Innovation Center at the company’s global headquarters. The center expands beyond imaging to demonstrate an end-to-end solution that addresses challenges associated with every step in the sample prep-to-report pipeline for assays performed on complex 3D biological models.

READ MORE

An Epigenetic Signature for COVID-19 Severity?

News

An article published in the journal EBiomedicine by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute and Dr. Aurora Pujol, head of the Neurometabolic Diseases Group of the Bellvitge Biomedical Research Institute (IDIBELL), shows that the epigenetic endowment of each person influences the severity of the COVID-19 disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE